 CAMBRIDGE, Mass., Nov. 04, 2020 GLOBE NEWSWIRE -- Mersana Therapeutics, Inc. NASDAQ:MRSN, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ADCs targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Wednesday, November 11, at 11:00 a.m. ET. 